10 March 2022 - Roche is negotiating with the government over the reimbursement price of Tecentriq (atezolizumab), which passed the review of HIRA in January.

Depending on the result, the use of Avastin (bevacizumab) in combination with Tecentriq in liver cancer can be expanded. This could affect the budding biosimilar market in Korea, too, observers said.

Read Korea Biomedical Review article